Welcome to our dedicated page for Genvor news (Ticker: GNVR), a resource for investors and traders seeking the latest updates and insights on Genvor stock.
Genvor Inc. (GNVR) news covers developments in peptide-based crop protection, sustainable agriculture, and agricultural biotechnology. As a developer of plant health solutions leveraging patented and proprietary peptides, Genvor regularly reports on research progress, intellectual property milestones, and collaborations that shape its role in the agricultural inputs sector.
News updates include announcements about peer-reviewed publications with the USDA Agricultural Research Service, such as studies on broad-spectrum antimicrobial peptides GV-185 and GV-187, as well as details on Cooperative Research and Development Agreements focused on reducing aflatoxin contamination and other plant disease challenges. Investors and industry participants can also follow coverage of Genvor’s U.S. patents, including a patent co-assigned with the USDA on transgenic corn expressing an antifungal peptide designed to combat fungal infections and mycotoxin production.
Genvor’s news flow highlights research partnerships and teaming agreements, including its collaboration with Tuskegee University’s Center for Biomedical Research and multiple R&D collaborations across Europe, Brazil, and the United States. These stories often describe field trials, greenhouse trials, and the evaluation of peptide-based foliar formulations and seed traits under diverse conditions.
Coverage also extends to capital markets milestones such as OTCQB Venture Market listing status and corporate updates, as well as participation in industry conferences like the BioAgTech World Congress, World Agri-Tech Innovation Summit, and BioSolutions Conference & Expo. For readers tracking GNVR, this news page provides a focused view of how Genvor’s peptide technologies, partnerships, and licensing-first business model evolve over time.
Genvor (OTCQB: GNVR) announced a strategic expansion into the human health and wellness market on March 4, 2026, leveraging its proprietary BioCypher AI-driven peptide platform.
The company said its library contains millions of designed peptides, with dozens of agricultural lead candidates across more than a dozen pathogens, and will now advance consumer-focused recovery, performance, anti-aging, and daily wellness peptide products via a dual commercialization model.
Genvor also realigned senior leadership, assigning George Stavrides expanded oversight of agricultural commercialization while CEO Chad Pawlak focuses on capital markets and consumer partnership development.
Genvor (OTCQB: GNVR) announced peer-reviewed validation of its AI-designed antifungal peptide AGM182 in PhytoFrontiers, reporting greenhouse results showing 76–98% reduction in total aflatoxin contamination in transgenic corn expressing AGM182.
The publication, co-authored with USDA-ARS, cites no adverse plant growth effects, a proven mammalian safety profile, activity versus Aspergillus flavus and Fusarium species, and follows U.S. Patent No. 12,458,684 co-assigned with USDA-ARS.
Genvor (OTCQB: GNVR) appointed Dr. George Stavrides as Executive Vice President, Business Development & Commercialization, effective February 2, 2026. Dr. Stavrides brings 15+ years in agrochemical and biological product management, including roles at Syngenta where he oversaw >50 global product launches and helped quadruple revenues over seven years.
He will lead commercial strategy, partnerships, licensing and collaboration efforts to advance Genvor’s AI-accelerated peptide platform and expand market access to growers worldwide.
Genvor (OTC: GNVR) will present at the 3rd Annual DealFlow Discovery Conference on January 28-29, 2026, at The Borgata Hotel, Casino & Spa in Atlantic City, New Jersey.
Co-Founder Clayton Yates, MS, Ph.D. will deliver a company presentation on January 28 at 11:00 AM EST and will be available for one-on-one investor meetings during the event. The presentation will describe how Genvor’s AI-accelerated peptide platform targets plant pathogens linked to an estimated $220 billion in annual crop losses.
Genvor (OTC: GNVR) entered a formal teaming agreement with Tuskegee University on December 2, 2025 to accelerate peptide-based technologies for sustainable crop protection.
The collaboration establishes joint research, testing, and grant-supported development, giving Genvor access to Tuskegee research laboratories, instrumentation, and student talent to expand scientific validation and field application of Genvor’s proprietary peptide active ingredients.
Genvor (OTCQB: GNVR) announced the USPTO issued U.S. Patent No. 12,458,684 on Nov 12, 2025 for “Transgenic Corn with Antifungal Peptide AGM182,” co‑assigned to Genvor and the USDA. The patent covers transgenic corn expressing AGM182 designed to reduce fungal infections and mycotoxin accumulation, including activity shown against Aspergillus flavus and Fusarium species.
Published results cited in Plant Science and Plant Disease report 76–98% reduction in total aflatoxin contamination, no adverse plant growth or yield effects, and no observed mammalian toxicity. The company highlights potential foliar spray and transgenic seed applications to address multi‑billion dollar U.S. corn losses from fungal diseases.
Genvor (OTCID: GNVR) regained active OTCQB trading status on October 9, 2025, positioning the company to accelerate capital formation as it scales field trials and commercialization efforts.
The company said it now operates a newly opened laboratory in Woodland, California to support R&D for foliar and peptide-based formulations, and it is advancing four international research collaborations across Europe, Brazil, and the United States focused on peptide-based seed traits and foliar applications.
Management highlighted that these developments support product validation, global field trials, and expanded scientific capabilities for sustainable agriculture.
Summary not available.
Summary not available.
Summary not available.